Objective: To assess the impact of a population-based disease management programme for adult patients with asthma or chronic obstructive pulmonary disease (COPD) on process measures, intermediate outcomes, and endpoints of care.
Design: Quasi-experimental design with 12-month follow-up.
Setting: Region of Maastricht (the Netherlands) including university hospital and 16 general practices.
Participants: Nine hundred and seventy-five patients of whom 658 have asthma and 317 COPD.
Intervention: Disease management programme.
Main Outcome Measure(s): Endpoints of care are respiratory health, health utility, patient satisfaction, and total health care costs related to asthma or COPD.
Results: Quality aspects of care, disease control, self-care behaviour, smoking status, disease-specific knowledge, and patients' satisfaction improved after implementation of the programme. Lung function was not affected by implementation of the programme. For COPD patients, a significant improvement in health utility was found. For patients with asthma, significant cost savings were measured.
Conclusions: Organizing health care according to principles of disease management for adults with asthma or COPD is associated with significant improvements in several processes and outcomes of care, while costs of care do not exceed the existing budget.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/intqhc/mzl052 | DOI Listing |
Hum Immunol
January 2025
Laboratory of Immunogenetics and Tissue Immunology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Atopic dermatitis (AD) is one of the most common dermatoses. According to current data 2.6 % of the world's population suffer from AD.
View Article and Find Full Text PDFTransl Oncol
January 2025
Johns Hopkins Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA. Electronic address:
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on their gene expression. We comprehensively characterized nine human BLCA cell lines (UC3, UC6, UC9, UC13, UC14, T24, SCaBER, RT4V6 and RT112) into molecular subtypes using orthotopic xenograft models.
View Article and Find Full Text PDFHepatology
January 2025
Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, CA.
Background Aims: Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS criteria ("All-comers" (AC)) have been limited by small sample size and short follow-up time, prompting this analysis.
Approach Results: 326 patients meeting UNOS-DS and 190 meeting AC criteria from 9 LT centers across 5 UNOS regions were enrolled from 2015 to 2023 and prospectively followed.
J Strength Cond Res
December 2024
School of Kinesiology, University of Michigan, Ann Arbor, Michigan.
Motlagh, JG and Lipps, DB. The contribution of muscular fatigue and shoulder biomechanics to shoulder injury incidence during the bench press exercise: A narrative review. J Strength Cond Res 38(12): 2147-2163, 2024-Participation in competitive powerlifting has rapidly grown over the past two decades.
View Article and Find Full Text PDFJ Strength Cond Res
December 2024
School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, United Kingdom.
Kember, LS, Riehm, CD, Schille, A, Slaton, JA, Myer, GD, and Lloyd, RS. Residual biomechanical deficits identified with the tuck jump assessment in female athletes 9 months after ACLR surgery. J Strength Cond Res 38(12): 2065-2073, 2024-Addressing biomechanical deficits in female athletes after anterior cruciate ligament reconstruction (ACLR) is crucial for safe return-to-play.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!